Lv5
870 积分 2021-08-02 加入
Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma
21天前
已完结
Sintilimab Plus Axitinib for Advanced Fumarate Hydratase–Deficient Renal Cell Carcinoma
22天前
已完结
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
1个月前
已完结
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
1个月前
已完结
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
1个月前
已完结
Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial
2个月前
已完结
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
4个月前
已完结
Enfortumab vedotin plus pembrolizumab effective in patients with resectable bladder cancer
4个月前
已完结
Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer
4个月前
已完结
The impact of integrating PRIMARY score or SUVmax with MRI-based risk models for the detection of clinically significant prostate cancer
4个月前
已完结
皖公网安备34019202002308
